In line with this, the NCCN Clinical Practice Guidelines in Oncology advise evaluating mutations in KRAS, NRAS, and BRAF, as well as MSI status, to enable personalized therapy selection and improve patient stratification in CRC [36]. This evidence concerns the gene NRAS and colorectal carcinoma.